scPharmaceuticals Inc. (NASDAQ:SCPH) Stock Holdings Cut by Nuveen Asset Management LLC

Nuveen Asset Management LLC cut its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 49.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 90,503 shares of the company's stock after selling 89,150 shares during the period. Nuveen Asset Management LLC owned approximately 0.18% of scPharmaceuticals worth $320,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in shares of scPharmaceuticals by 9.0% in the 4th quarter. Bank of America Corp DE now owns 44,037 shares of the company's stock valued at $156,000 after buying an additional 3,647 shares during the period. Corebridge Financial Inc. increased its stake in shares of scPharmaceuticals by 29.0% during the fourth quarter. Corebridge Financial Inc. now owns 19,586 shares of the company's stock worth $69,000 after acquiring an additional 4,406 shares during the period. Balanced Rock Investment Advisors LLC lifted its holdings in scPharmaceuticals by 8.7% in the fourth quarter. Balanced Rock Investment Advisors LLC now owns 70,362 shares of the company's stock valued at $249,000 after acquiring an additional 5,612 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in scPharmaceuticals by 31.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 23,471 shares of the company's stock worth $84,000 after buying an additional 5,633 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of scPharmaceuticals by 36.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,973 shares of the company's stock worth $78,000 after acquiring an additional 5,827 shares during the period. Hedge funds and other institutional investors own 89.52% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, March 20th. Maxim Group lowered their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 20th.

scPharmaceuticals Stock Up 1.2%

SCPH stock traded up $0.05 during mid-day trading on Monday, hitting $4.25. 189,768 shares of the company were exchanged, compared to its average volume of 368,824. scPharmaceuticals Inc. has a twelve month low of $1.94 and a twelve month high of $5.65. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $224.37 million, a PE ratio of -2.24 and a beta of 0.36. The firm has a fifty day simple moving average of $2.81 and a 200 day simple moving average of $3.14.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $11.75 million during the quarter, compared to analyst estimates of $11.63 million. On average, research analysts forecast that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.